Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs General Mills, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.2 (market cap $39.89B), while General Mills, Inc. trades at $36.98 (market cap $19.33B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× General Mills, Inc.'s market cap, and General Mills, Inc. pays a 6.74% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GIS | |
|---|---|---|
Market Cap | $39.89B | $19.33B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $51.60 |
52-Week Low | $278.09 | $32.17 |
Enterprise Value | $38.15B | $32.82B |
Dividend Yield | — | 6.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
General Mills (GIS) trades at $36.22, up 1.03% on the day, near the analyst consensus price target of $36.14. The stock presents a mixed picture with a low P/E of 9.23 suggesting value, but profitability metrics like a negative net income margin and ROE for 2026 signal challenges. Recent Q2 2026 earnings beat expectations, yet the technical outlook is bearish, and news highlights sales pressure and a focus on cost savings to drive a margin recovery in fiscal 2027.
The investment outlook is cautious. The stock's low valuation and dividend yield offer potential value, but persistent sales softness, margin pressure from competition, and a high debt-to-asset ratio of 45% pose significant risks. Analyst sentiment is predominantly neutral to negative, with a majority hold rating, indicating a wait-and-see approach is warranted until clearer signs of sustainable growth emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
